Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ilant Health vs Kin Meds

Ilant Health
Graded #408

Lower grade

vs+16.10000000000001
Kin Meds
Graded #75

Higher grade

The verdict

Kin Meds takes it — 72.9/100 to 56.8/100.

Kin Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKin Meds +29
45
74
Dose & formulationKin Meds +53
40
93
Clinical oversightIlant Health +9
83
74
Labs & monitoringIlant Health +8
61
53
FulfillmentKin Meds +10
62
72
Contract termsEven
55
55
Ilant Health · left barKin Meds · right bar

The numbers

MetricIlant HealthKin Meds
WeighScore56.8/10072.9/100
GradeCC
Scorecard rank#408#75
SemaglutideNot disclosed$149/mo (brand Wegovy)
TirzepatideNot disclosed$149/mo (brand Zepbound)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Ilant Health

Graded #408 · C

Strengths

  • Value-based, outcomes-driven obesity care model
  • Includes GLP-1 medications with transparent drug pricing for sponsors
  • Care team of board-certified obesity providers and behavioral specialists
  • Dietitians and peer navigators support adherence
  • Data-driven stratification targets the right interventions

Where it loses points

  • Distributed via employers and health plans, not direct cash-pay
  • Individuals generally cannot enroll without sponsor coverage
  • No public consumer pricing for GLP-1
  • Access gated behind organizational buyers
  • Not suited to consumers wanting direct-to-door GLP-1
Kin Meds

Graded #75 · C

Strengths

  • Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
  • Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
  • LegitScript verified
  • Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
  • Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health

Where it loses points

  • Legal entity name and state of incorporation not publicly disclosed
  • The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
  • Per-state availability not listed
  • $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
  • Lab work and dose-titration support not clearly described

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard